Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity

Journal of Oral and Maxillofacial Surgery

Volumn 61, Issue 7, 2003, Pages 774-778

  Von Lindern, Jens J ^a   Niederhagen, Bernd ^b   Bergé, Stefaan ^b   Appel, Thorsten ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BOTULISM; CONTROLLED STUDY; DYSTONIA; FACE PAIN; FUNCTIONAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MASTICATION; MASTICATORY MUSCLE; PARALYSIS; SPEECH DISORDER; VISUAL ANALOG SCALE;

EID: 0038579188     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-2391(03)00153-8     Document Type: Article

References (22)

1. Franks AST: The social character of TMJ dysfunction. Dent Pract 15:94, 1964
2. Schwartz LL: Temporomandibular joint syndrome. J Prosth Dent 7:489, 1957
3. Nishioka GJ, Montgomery MT: Masticatory muscle hyperactivity in temporomandibular disorders: Is it an extrapyramidally expressed disorder? J Am Dent Assoc 116:514, 1988
4. Reich RH, Roßbach A: Erscheinungsformen muskulärer Hyperaktivität im Kiefer und Gesichtsbereich. Dtsch Zahnärztl Z 43:11, 1988
5. Brin MF: Interventional neurology: Treatment of neurological conditions with local injection of botulinum toxin. Arch Neurobiol 54:7, 1991
6. Brin MF, Blitzer A, Green PE, et al: Botulinum toxin for the treatment of oromandibulolingual (OMD) dystonia. Neurology S1:294, 1989
7. Binz T, Blasi J, Yamaski S, et al: Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 169:1617, 1994
8. Giladi N: The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 152:132, 1997
9. Aoki R: The development of BOTOX: Its history and pharmacology. Pain Digest 8:337, 1998
10. Graber G: Was leistet die funktionelle Therapie und wo findet sie ihre Grenzen? Dtsch Zahnärztl Z 40:165, 1985
11. Schulte W: Zur funktionellen Behandlung der Myoarthropathien des Kauorgans Ein diagnostisches und physiotherapeutisches Programm. Dtsch Zahnärztl Z 25:422, 1970
12. Childers MK, Wilson DJ, Galate JF, et al: Treatment of painful muscle syndrome with botulinum toxin: A review. J Back Musculoskeletal Rehabil 10:89, 1998
13. Freund B, Schwartz M: The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health 2:32, 1998
14. Freud B, Schwartz M, Symington JM: Botulinum toxin: New treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38:466, 2000
15. Girdler NM: Use of botulinum toxin to alleviate facial pain. Br J Hosp Med 52:363, 1994 (letter)
16. Girdler NM: Uses of botulinum toxin. Lancet 349:953, 1997 (letter)
17. Capra NF, Bernanke JM, Porter JD: Ultrastuctural changes in the masseter muscle of macaca fascicularis resulting from intramuscular injection of botulinum toxin type. A Arch Oral Biol 36:827, 1991
18. Filippi GM, Errico P, Santarelli R, et al: Botulinum A toxin effect on jaw muscle spindles. Acta Otolaryngol (Stockh) 113:400, 1993
19. Guyer BM: Mechanism of botulinum toxin in the relief of pain. Curr Rev Pain 3:427, 1999
20. Rosales RL, Arimura K, Takenaga S, et al: Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerv 19:488, 1996
21. Ishikawa H, Mitsui Y, Yoshitomi T, et al: Presynaptic effects of botulinum toxin type A on the neuronally rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44:106, 2000
22. Benecke R, Hagenah R, Wiegand H: Effect of type A botulinum toxin on some synaptic transmission in the spinal cord of cats. Pflüglers Arch 359:90, 1975